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Abstract: Angiogenesis plays an important role in normal animal growth and development. This 
process is also vital for the growth of tumors. Angiogenesis inhibitors have a different mechanism 
of action to traditional chemotherapy agents and radiation therapy. The angiogenesis inhibitors 
can act synergistically with conventional treatments and tend to have non-overlapping toxicities. 
There are four drugs which have a proven role in treating cancer patients. Bevacizumab is a 
humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor 
(VEGF). Sunitinib and sorafenib inhibit multiple tyrosine kinase receptors that are important 
for angiogenesis. Thalidomide inhibits the activity of basic fibroblast growth factor-2 (bFGF). 
The licensed indications and the supporting evidence are discussed. Other drugs are currently 
being tested in clinical trials and the most promising of these drugs are discussed. Aflibercept, 
also known as VEGF-trap, is a recombinant fusion protein that binds to circulating VEGF. The 
vascular disrupting agents act by targeting established blood vessels. These exciting new treat-
ments have the potential to transform the management of cancer.
Keywords: angiogenesis, bevacizumab, tyrosine kinase inhibitors, thalidomide, aflibercept, 
vascular disrupting agents
Introduction
Angiogenesis is the process by which new blood vessels grow from existing 
vasculature. It is an essential part of embryonic development. Primitive vascular 
networks of endothelial cells undergo budding and branching before associating 
with vascular smooth muscle. This vasculature can then support its local tissues with 
nutrients and oxygen. This process continues in childhood where it is necessary for 
the growth of long bones. In adults, angiogenesis is called into play again in certain 
situations, eg, wound healing.
A tumor is unable to grow beyond 2 mm diameter without neoangiogenesis.1 
Tumor hypoxia leads to an “angiogenic switch” altering the balance between pro-
angiogenic and anti-angiogenic factors in favor of angiogenesis. Hypoxia occurs as the 
tumor outgrows its existing vascular supply. Hypoxia-inducible factor-1 production 
leads to increased vascular endothelial growth factor (VEGF) transcription.2 VEGF 
causes increased vessel permeability and endothelial cell migration and proliferation. 
Hypoxia can also lead to increased production of other pro-angiogenic molecules 
such as nitric oxide synthase, platelet-derived growth factor (PDGF), transforming 
growth factors alpha and beta, basic fibroblastic growth factor (bFGF), and a class of 
protein growth factors called the angiopoietins. VEGF is probably the most important 
of these factors.3,4OncoTargets and Therapy 2010:3 70
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VEGF (also known as VEGF-A) is one member of a 
supergene family of growth factors. The other members are 
VEGF-B, VEGF-C, VEGF-D, PDGF and placental growth 
factor (PlGF).
These pro-angiogenic growth factors bind to receptor 
tyrosine kinases (RTKs) on the cell surface. These include 
PDGF receptors (PDGFRα and PDGFRβ), VEGF receptors 
(VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor 
(KIT), Fms-like tyrosine kinase 3 (FLT3), colony stimulat-
ing factor receptor type 1 (CSF-1R) and the glial cell-line 
derived neurotrophic factor receptor RET.
Activation of the VEGF receptor leads to signaling 
via the Ras/Raf/MEK/ERK pathway. VEGFR activation 
can also trigger intracellular signaling by phosphorylat-
ing other proteins such as phospholipase C-γ (PLC-γ), 
focal adhesion kinase (FAK), p38 and phosphoinositide 
3′-kinase (PI3K).
Receptor tyrosine kinase inhibitors compete with 
adenosine triphosphate (ATP) for the ATP-binding site of 
the catalytic domain of the tyrosine kinase. RTK inhibitors 
thereby prevent the intracellular signaling which leads to 
angiogenesis.
It is possible that VEGF inhibitors produce a paradoxi-
cal increase in tumor blood flow and oxygenation due to 
“normalization” – the selective elimination of poorly 
formed blood vessels.5 This could lead to enhanced delivery 
of cytotoxic chemotherapy drugs to the tumor. Radiation 
therapy depends on tumor oxygenation6,7 and it is possible 
that an increase in tumor oxygenation leads to synergism 
between radiation therapy and VEGF inhibitors.
Angiogenesis inhibitors have a different mechanism of 
action and tend to have non-overlapping toxicities with cyto-
toxic chemotherapy and radiation therapy. There is therefore 
a logical rationale for combining these treatments.
The tumor vasculature differs from normal blood vessels 
in several ways (Table 1). These differences are exploited by 
a group of drugs called vascular disrupting agents (VDAs).
The aim of this review is to provide a summary of the 
most important anti-angiogenesis cancer therapies with their 
current indications and potential future uses.
Bevacizumab
Bevacizumab was the first angiogenesis inhibitor to be devel-
oped and used in the clinic.
Bevacizumab is a humanized monoclonal antibody that 
inhibits angiogenesis by binding to VEGF. The binding of 
bevacizumab to VEGF prevents VEGF binding to its recep-
tors on the surface of endothelial cells. Bevacizumab thereby 
prevents VEGF-induced increased vessel permeability and 
endothelial cell migration and proliferation.
Bevacizumab was first approved by the United States 
Food and Drug Administration (FDA) in February 2004 for 
patients with metastatic colorectal cancer and it has since 
been approved for use with other cancers. The development 
and FDA approval of this drug paved the way for other 
novel agents.
Colorectal cancer – palliative treatment
Metastatic colorectal cancer has been treated for many years 
with 5-fluorouracil (5-FU) and leucovorin (LV). The addi-
tion of oxaliplatin and irinotecan in recent years has further 
increased overall survival.
The landmark phase III study of bevacizumab by 
Hurwitz et al randomized 813 patients to irinotecan and 
5-FU/LV with or without bevacizumab. These patients all 
had previously untreated metastatic colorectal cancer. The 
patients who received bevacizumab had a higher response 
rate (44.8% versus 34.8% without bevacizumab, P = 0.004), 
median progression-free survival (PFS) (10.6 months versus 
6.2 months, hazard ratio [HR] 0.54, P  0.001), and over-
all survival (20.3 months versus 15.6 months, HR 0.66, 
P  0.001).9
The Eastern Co-operative Oncology Group (ECOG) 
E3200 phase III study examined the role of second-line 
chemotherapy with oxaliplatin, 5-FU and LV (FOLFOX4) 
in 825 patients who had previously received irinotecan-
based chemotherapy without bevacizumab. The patients 
who received FOLFOX4 with bevacizumab had an improved 
median survival of 12.9 months compared to 10.8 months 
with FOLFOX4 alone (P = 0.0011). There was also an arm 
of the trial with bevacizumab alone but this was closed early 
due to poor overall response rates and PFS.10
The N016966 phase III trial evaluated the use of beva-
cizumab as first-line therapy with fluoropyrimidine (5-FU 
or capecitabine) and oxaliplatin-based chemotherapy in 
Table 1 Features of tumor vasculature compared to normal blood 
vessels8
Increased vessel tortuosity
Vessels thin walled and fragile
Increased interstitial pressure within tumor
Vessel marker immaturity
Increased vessel permeability
Variable flow rates
Lack of vascular smooth muscle
Constant remodelingOncoTargets and Therapy 2010:3 71
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1,401 patients. The addition of bevacizumab significantly 
improved PFS (9.4 months versus 8.0 months in the pla-
cebo group, P = 0.0023) and there was a trend towards 
improved overall survival (21.3 months versus 19.9 months, 
P = 0.077).11
There are currently no results from randomized trials 
to indicate whether bevacizumab should be continued with 
second-line chemotherapy after failure of first-line chemo-
therapy with bevacizumab. Retrospective, observational 
data from the BRiTE study suggest there may be improved 
survival with continuation of bevacizumab.12
Unfortunately, bevacizumab does not confer significant 
additional benefit with 5-FU/LV alone in the context of third-
line chemotherapy. TRC-0301 was a phase II study which 
enrolled 350 patients who were refractory to oxaliplatin and 
irinotecan. All patients received bevacizumab with 5-FU/LV . 
The overall response rate by independent assessors was 1% 
(95% confidence interval [CI] 0% to 5.5%). The median 
PFS was 3.5 months and the median overall survival was 
9.0 months.13
Colorectal cancer – adjuvant treatment
Interest is currently focused on the adjuvant setting. The 
National Surgical Adjuvant Breast and Bowel Project 
(NSABP) C-08 study compared modified FOLFOX6 
(mFOLFOX6) with and without bevacizumab.14 This study 
randomized 2672 patients with stage II (24.9%) or stage III 
carcinoma of the colon and had a median follow up of 
36 months. The addition of bevacizumab did not improve 
3 year disease-free survival (HR 0.89, 95% CI 0.76 to 1.04, 
P = 0.15). There was a statistically significant benefit in 
prolongation of disease-free survival during the 1 year that 
bevacizumab was administered but this benefit was tran-
sient.15 It is possible that bevacizumab is acting differently in 
the context of microscopic disease. Bevacizumab may only 
have a cytostatic effect in this context.
Results are awaited from the AVANT study which is evalu-
ating FOLFOX4 versus FOLFOX4 plus bevacizumab versus 
oxaliplatin with capecitabine (XELOX) plus bevacizumab.16 
ECOG E5202 is studying FOLFOX6 with and without bevaci-
zumab. This trial continues to recruit patients. It is anticipated 
that the 3 year disease-free survival data will be available by 
April 2011.17 QUASAR 2 is investigating capecitabine with 
and without bevacizumab. This trial should complete recruit-
ment in March 2010 and report in December 2013.18
The FDA have approved the use of bevacizumab in com-
bination with chemotherapy in the first-line and second-line 
treatment of metastatic colorectal cancer.19
Breast cancer – palliative treatment
Patients with human epidermal growth factor receptor-2   
(HER-2) negative disease were the first breast cancer patients 
to be studied with bevacizumab.
The ECOG E2100 trial was a first-line therapy, open-
label phase III trial that enrolled 722 patients with metastatic 
breast cancer. They were randomized to have paclitaxel with 
or without bevacizumab. The patients who received bevaci-
zumab had a higher objective response rate (36.9% versus 
21.2%, P  0.001) and a greater median PFS (11.8 months 
versus 5.9 months, HR 0.60, P  0.001). There was no sig-
nificant difference in median overall survival (26.7 months 
versus 25.2 months, HR 0.88, P = 0.16).20
The AVADO phase III trial enrolled 736 women with 
locally recurrent or metastatic breast cancer to one of three 
groups. Patients were randomized to receive either bevaci-
zumab 15 mg/kg, 7.5 mg/kg or placebo. Compared to the 
placebo group, the 7.5 mg/kg group had a PFS HR of 0.69 
(95% CI 0.54 to 0.89) and a HR of 0.61 (95% CI 0.48 to 
0.78) for the 15 mg/kg group. The median survival data are 
not available yet.21
The RIBBON-1 trial randomized 1,237 patients to have 
first-line chemotherapy for locally recurrent or metastatic 
breast cancer with bevacizumab or placebo and the physi-
cian’s choice of chemotherapy. Compared to the placebo 
group, the PFS HR with bevacizumab was 0.688 (95% CI 
0.564 to 0.840) in the capecitabine group and 0.644 (0.522 
to 0.795) in the pooled taxane and anthracycline group.22
The addition of bevacizumab to third-line chemotherapy 
does not confer additional benefit. A phase III trial by Miller 
et al randomized 462 patients to receive capecitabine alone or 
in combination with bevacizumab. These patients had all pre-
viously received an anthracycline and a taxane. The response 
rate was higher with combination therapy (19.8% versus 
9.1% with capecitabine alone, P = 0.001) but there was no 
significant difference in PFS (4.86 versus 4.17 months) or 
overall survival (15.1 versus 14.5 months).23 It appears that 
patients with such refractory disease respond differently to 
those given bevacizumab earlier in the course of their dis-
ease. It is possible that patients with refractory disease have 
several different angiogenic pathways which are activated 
and it would require more than a single anti-angiogenic drug 
to overcome this.
The US FDA has approved the use of bevacizumab in 
the first-line treatment of HER-2 negative metastatic breast 
  cancer.19 This decision was controversial. Some physicians 
were concerned that there was no proven overall survival 
  benefit. The FDA, however, justified its decision on the OncoTargets and Therapy 2010:3 72
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following grounds. Progression-free survival (PFS) had 
already been used as the primary endpoint for the approval 
of chemotherapy and hormonal therapy for metastatic breast 
cancer patients. Only a small number of the existing random-
ized, phase III trials in metastatic breast cancer patients for 
established drugs had actually shown a survival benefit. Fur-
thermore, first-line trials in metastatic breast cancer patients 
would need to enroll enough patients to observe 2000 deaths 
in order to demonstrate, with 80% power, an improvement 
of 3 months in overall survival.24
Breast cancer – adjuvant treatment
With the approval of bevacizumab for use in metastatic breast 
cancer patients, the next logical question is whether adjuvant 
breast cancer patients would benefit too.
The ECOG E2104 study was a phase II trial of bevaci-
zumab in addition to dose dense doxorubicin and cyclophos-
phamide followed by paclitaxel in patients with lymph node 
positive breast cancer.25 This study showed that bevacizumab 
can be safely incorporated into anthracycline-containing 
regimens without causing cardiac dysfunction.26 This has 
led to the following studies.
The BEATRICE study is a phase III trial investigat-
ing standard adjuvant chemotherapy with or without 
bevacizumab for patients with hormone receptor and HER-2   
receptor negative breast cancer. The standard chemotherapy 
can be anthracycline or taxane-based or a combination of 
both. This trial has not yet completed accrual.27
The NSABP BETH study is a phase III trial of patients 
with HER-2 positive, lymph node positive or high risk node 
negative breast cancer patients. The standard chemotherapy 
is taxane-based or a combination of a taxane and anthra-
cycline sequentially. All patients receive trastuzumab with 
or without concurrent bevacizumab. This trial continues to 
accrue patients.28
Non-small cell lung cancer
It has been shown that bevacizumab is of benefit in selected 
patients with non-small cell lung cancer (NSCLC).
The ECOG E4599 study was a phase III trial involving 
878 patients with previously untreated advanced NSCLC. 
Patients with squamous cell carcinoma, hemoptysis, brain 
metastases and those on therapeutic anticoagulation were 
excluded to reduce the risk of pulmonary or cerebral hemor-
rhage. The patients were treated with 6 cycles of carboplatin 
and paclitaxel chemotherapy with or without bevacizumab. The 
median PFS was 6.2 months in the bevacizumab arm versus 
4.5 months with chemotherapy alone (HR 0.66, P  0.001). 
The median overall survival was 12.3 months versus 
10.3 months without bevacizumab (HR 0.79, P = 0.003). 
Unfortunately, there were more treatment-related deaths in 
the bevacizumab arm (15 patients) than in the chemotherapy 
alone arm (2 patients). These 15 deaths included 5 deaths from 
hemoptysis and 2 due to hematemesis.29 There is therefore an 
improvement in overall survival but with an increased risk of 
treatment-related death. One must balance the risks against 
potential benefits when prescribing for this patient group.
The AVAiL study was a randomized phase III trial 
involving 1,043 patients with advanced NSCLC and ECOG 
performance status of 0 or 1. Patients received cisplatin and 
gemcitabine with placebo or low-dose bevacizumab or high-
dose bevacizumab. Patients with squamous cell carcinoma, 
a history of hemoptysis or cerebral metastases were excluded. 
The median PFS was higher with low-dose bevacizumab 
(HR 0.75, P = 0.003) and high-dose bevacizumab (HR 
0.82, P = 0.03) compared to placebo. The trial was not 
sufficiently powered to detect a difference between the two 
different doses. The incidence of grade 3 or greater toxicities 
were similar in all three arms of the trial.30 The incidence 
of grade 3 pulmonary hemorrhage was 1.5% or less for 
all three arms despite 9% of patients receiving therapeutic 
anticoagulation. There was no difference in overall survival 
between the three groups with a median survival of 13.6, 13.4 
and 13.1 months for the low-dose, high-dose and placebo 
arms, respectively.31
The FDA has approved the use of bevacizumab for the 
first-line treatment of advanced NSCLC.19
Glioblastoma multiforme
The AVF3708g study was a phase II trial of bevacizumab 
given as a single agent or in combination with irinotecan in 
167 patients with recurrent glioblastoma multiforme. All 
patients had received prior treatment with temozolomide. 
The initial results show objective response rates of 20% with 
bevacizumab alone or 33% in combination with irinotecan. 
The 6-month PFS rates were 35% and 50%, respectively. The 
overall survival was 9.2 months and 8.7 months respectively. 
These are encouraging results for this group of patients with 
a relatively poor prognosis.32
The National Cancer Institute (NCI) 06-C-0064E study 
investigated single-agent bevacizumab in 56 patients with 
recurrent glioblastoma multiforme. They all had previous 
surgery, radiation therapy and temozolomide or other sys-
temic therapy. The objective response rate was 19.6%. The 
6-month PFS rate was 29%. The median overall survival 
was 31 weeks.33OncoTargets and Therapy 2010:3 73
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The results of these two trials led to fast-track approval of 
bevacizumab for glioblastoma multiforme by the FDA.19
Metastatic renal cell carcinoma
The AVOREN (BO17705) trial was a phase III trial of 
interferon-α (IFN-α) -2a with or without bevacizumab in 
649 patients with metastatic renal cell carcinoma. The median 
PFS was significantly longer in the group that received beva-
cizumab (10.2 months versus 5.4 without bevacizumab, HR 
0.63, 95% CI 0.52 to 0.75, P = 0.0001). Increases in PFS 
were observed irrespective of risk group or whether reduced 
dose IFN-α was used. Deaths due to adverse events were 
similar in both groups. There were 3 deaths that may have 
been related to bevacizumab.34
The CALGB 90206 study was a phase III trial using 
IFN-α with and without bevacizumab in 732 patients with 
metastatic renal cell carcinoma. The initial results show that 
the median time to progression was 8.5 months with beva-
cizumab and 5.2 months with IFN-α alone (HR 0.71, 95% 
CI 0.61 to 0.83, P  0.0001).35
The FDA has approved bevacizumab for use with IFN-α 
in metastatic renal cell carcinoma.19
Combination with radiation therapy
There is one completed phase II study examining the role 
of bevacizumab with radiation therapy. Bevacizumab was 
given with 5-FU and radiation therapy to 32 patients prior to 
surgery for locally advanced rectal cancer. The treatment was 
generally well tolerated – most toxicities were grade 1 or 2 
although there were 7 patients with grade 3 diarrhea and 
3 patients with grade 3 hypertension. The tumor regressed 
in all patients with a mean size of 5 cm (range 3 to 12 cm) 
to an ulcer or scar with a mean size of 2.4 cm (range 0.7 to 
6 cm). Histologic examination revealed either no cancer cells 
or scattered cancer cells in a bed of fibrosis.36
There is a phase II study of patients having post-operative 
treatment of glioblastoma multiforme with radiation therapy 
and concurrent temozolomide and bevacizumab. Patients 
receive external beam radiation therapy of  60 Gy in 30 
fractions. This is given with temozolomide and bevacizumab 
during and after radiation therapy. An interim report in 2007 
on the first 10 patients showed that the toxicities were accept-
able.37 The authors are continuing this study and they aim to 
recruit a total of 70 patients. This treatment is now also being 
evaluated in two randomized phase III trials which continue 
to recruit patients.38,39
There are also a large number of phase II trials in progress 
evaluating bevacizumab with radiation therapy in a variety 
of tumor sites including cervical cancer, pancreatic cancer, 
prostate cancer, lung cancer and sarcomas.
Adverse effects
The overall safety profile of bevacizumab has been compiled 
from data on over 3,500 patients with various malignan-
cies. The most serious adverse effects were gastrointestinal 
perforation, hemorrhage (with hemoptysis occurring more 
commonly in non-small cell lung cancer patients), and arte-
rial thromboembolism.
The risk of gastrointestinal perforation is generally less 
than 1% but up to 2% in colorectal cancer patients. The risk 
of grade 3–5 hemorrhage ranged from 0.4% to 5% in studies 
with bevacizumab versus up to 2.9% in the control groups. 
The rate of arterial thromboembolism was up to 3.8% with 
bevacizumab compared to 1.7% in the study control groups. 
The most common adverse effects include hypertension 
(in up to 34% of patients) and proteinuria (up to 38%). 
Grade 4 hypertension only occurs in 1.0% of patients and 
grade 4 proteinuria is experienced by 1.4% of patients.40
Tyrosine kinase inhibitors
The tyrosine kinase inhibitors were the next class of drugs 
to be developed.
The small size of the RTK inhibitors allows them to enter 
cells whereas the much larger monoclonal antibodies can only 
bind to the cell surface. There are a number of tyrosine kinase 
inhibitors currently under development (Table 2).
Sorafenib first received approval for the treatment of 
patients with advanced renal cell cancer in December 2005. 
Shortly afterwards, in January 2006, sunitinib received FDA 
approval for the treatment of advanced renal cell cancer and 
gastrointestinal stromal tumors.
Sorafenib
Sorafenib is an oral multi-targeted tyrosine kinase inhibitor. 
It was originally developed as an inhibitor of Raf-1 which 
is vital for cell proliferation. Sorafenib is also an inhibitor 
of VEGFR2 and 3, PDGFR-β, FLT3 and KIT.41
Renal cell carcinoma
A phase II study of sorafenib in renal cell carcinoma has 
yielded promising results. This study recruited 202 patients 
with renal cell carcinoma. Of the 193 evaluable patients, 70% 
were progression-free at 12 weeks. These patients were ran-
domized to receive sorafenib or placebo. The median PFS 
for patients after randomization was 23 weeks with sorafenib 
and 6 weeks with placebo (P = 0.0001).42OncoTargets and Therapy 2010:3 74
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This was followed by the phase III multinational TARGET 
trial, which was a double-blind, placebo-controlled trial 
of sorafenib. This trial recruited 903 patients of low- and 
intermediate-risk clear cell renal carcinoma. These patients 
had failed previous cytokine therapy. The primary endpoint 
was overall survival. The median PFS was 5.5 months in the 
sorafenib group and 2.8 months in the placebo group (HR 0.44, 
P  0.01). Following the interim analysis, patients on placebo 
were allowed to crossover to receive sorafenib. An interim 
analysis of overall survival showed that sorafenib reduced the 
risk of death, as compared with placebo (HR 0.72, P = 0.02).43 
The final analysis of this data was presented at the American 
Society of Clinical Oncology (ASCO) 2007 meeting. It showed 
that patients treated with sorafenib had a median survival of 
17.8 months versus 15.2 months with placebo. Although this 
was not statistically significant, the crossover of patients from 
placebo to sorafenib may have decreased the magnitude of the 
difference between the two groups. Response rates were lower 
than expected with partial responses reported in 10% of patients 
receiving sorafenib, while 78% showed stable disease.44
The FDA has approved the use of sorafenib in advanced 
renal cell carcinoma based on this data.45
Hepatocellular carcinoma
In the phase III SHARP trial, sorafenib was compared to 
placebo in 602 patients with biopsy-proven hepatocellular 
carcinoma. The median overall survival was 10.7 months 
in the sorafenib group versus 7.9 months for the placebo 
group (HR 0.69, P  0.001). In addition, the median time to 
progression was in favor of sorafenib at 5.5 months versus 
2.8 months in the placebo group (P  0.001).46
On the basis of these data, the FDA has approved the 
use of sorafenib in patients with unresectable hepatocellular 
carcinoma.45
Table 2 Current phase III randomized controlled trials of   VEGF tyrosine kinase inhibitors
Drug Indication
Axitinib
(AG-013736)
First-line or second-line therapy for metastatic renal cell cancer
First-line therapy for locally advanced, unresectable or metastatic pancreatic cancer (in combination with gemcitabine)
BIBF 1120 First-line therapy for ovarian cancer (in combination with paclitaxel and carboplatin)
Second-line therapy for advanced NSCLC (in combination with docetaxel)
Second-line therapy for advanced NSCLC (in combination with pemetrexed)
Brivanib alaninate 
(BMS-540215)
Adjuvant treatment following trans-arterial chemo-embolization (TACE) for hepatocellular carcinoma
First-line treatment of hepatocellular carcinoma
Second-line treatment of hepatocellular carcinoma
Following irinotecan and oxaliplatin for metastatic colorectal cancer (in combination with cetuximab)
Cediranib 
(AZD2171)
First-line treatment of metastatic colorectal cancer (in combination with oxaliplatin and a fluoropyrimidine)
Recurrent glioblastoma (alone and in combination with lomustine)
First-line therapy of advanced NSCLC
Relapsed ovarian epithelial, fallopian tube or primary peritoneal cancer (in combination with carboplatin and paclitaxel)
Pazopanib
(GW786034)
Ovarian, fallopian tube or primary peritoneal cancer (immediately after first-line chemotherapy)
Relapsed or progressive inflammatory breast cancer (in combination with lapatinib)
First-line therapy for locally advanced or metastatic renal cell carcinoma
Relapsed or progressive metastatic soft tissue sarcoma
Adjuvant therapy in stage I NSCLC
Motasenib (AMG 706) Advanced NSCLC (in combination with paclitaxel and carboplatin)
Semaxinib 
(SU5416)
First-line therapy for metastatic colorectal cancer (in combination with leucovorin and 5-fluorouracil)
First-line therapy for metastatic colorectal cancer (in combination with leucovorin, 5-fluorouracil and irinotecan)
Sorafenib
(BAY 43-9006)
Multiple trials in hepatocellular carcinoma, renal cell cancer, melanoma, pancreatic cancer,  
NSCLC, differentiated thyroid cancer
Sunitinib (SU11248) Multiple trials in renal cell carcinoma, GIST, breast cancer, pancreatic cancer, NSCLC, colorectal cancer
Vandetanib 
(AZD6474)
Second-line therapy for NSCLC (in combination with pemetrexed)
Second-line therapy for NSCLC (in combination with docetaxel)
Second-line therapy for NSCLC
Following failure of EGFR TKI in NSCLC
Vatalanib 
(PTK787/ZK222584)
First-line therapy for metastatic colorectal cancer (in combination with leucovorin, 5-fluorouracil and oxaliplatin)
Irinotecan-resistant metastatic colorectal cancer (in combination with leucovorin, 5-fluorouracil and oxaliplatin)
Notes: All data from clinicaltrials.gov, accessed December 13, 2009.
Abbreviations: EGFR, epidermal growth factor receptor; GIST, gastro-intestinal stromal tumor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.OncoTargets and Therapy 2010:3 75
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Adverse effects
In phase III studies, sorafenib caused diarrhea in 38% to 39% 
of patients compared to 9% of patients receiving placebo. 
Hand-foot syndrome occurred in 18%–19% of patients 
compared to 2% to 3% of patients taking placebo. Alope-
cia, anorexia and weight loss were also more common with 
sorafenib. There were relatively few grade 3 or 4 adverse 
effects. The only grade 3 adverse effects with sorafenib that 
occurred in more than 5% of patients were diarrhea (2% to 
8%) and hand-foot syndrome (4% to 7%). Grade 4 toxicities 
were reported in less than 1% of patients.47
Sunitinib
Sunitinib is an orally bioavailable agent that inhibits multiple 
RTKs. Sunitinib has been identified as an inhibitor of various 
RTKs including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, 
VEGFR3, KIT, FLT3, CSF-1R and RET.48
Renal cell carcinoma
Two phase II clinical trials have evaluated the role of suni-
tinib in patients with renal cell carcinoma (RCC).
In the first study, 63 patients with advanced RCC who 
had failed first-line cytokine therapy were enrolled. The 
majority had clear cell carcinoma. The response rate was 
40% and the duration of response was 8.7 months.49 The 
second study recruited 106 patients. They all had clear 
cell carcinoma and had failed previous cytokine treatment. 
There was a 34% partial response rate and the median PFS 
was 8.3 months.50 In the pooled results from these two stud-
ies, the partial response rate was 42%. The median PFS in 
the combined analysis was 8.2 months. In the patients who 
had a complete or partial response, the median PFS was 
14.8 months. In patients with stable disease for 3 months of 
more, the median PFS was 7.9 months.51
A randomized phase III trial compared sunitinib to IFN-α 
in the first-line treatment of patients with metastatic clear cell 
RCC. There were 375 patients in each arm of the trial. The 
median PFS for sunitinib was 11 months versus 5 months for 
IFN (HR 0.42, P  0.001). The response rate in the sunitinib 
arm was 31% versus 6% for IFN. Median overall survival 
had not been reached in either treatment arm at the time of 
the interim data analysis. The median overall survival was 
26.4 months in the sunitinib arm and 21.8 months in the 
IFN-α arm (HR 0.821, 95% CI 0.673 to 1.001, P = 0.051). 
Crossover to the sunitinib arm was allowed which might have 
decreased the magnitude of the difference observed.52
The FDA has approved the use of sunitinib in the first-line 
management of renal cell carcinoma.53
The role of sunitinib is being evaluated in the adjuvant 
setting in the Sunitinib treatment of Renal Adjuvant Cancer 
(S-TRAC) trial.54 Sunitinib is also being evaluated in the 
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Cell 
Carcinoma (ASSURE) trial.55
Gastro-intestinal stromal tumors
Patients with unresectable and metastatic gastro-intestinal 
stromal tumors (GISTs) have an improved PFS and overall 
survival when they are treated with imatinib.56 Imatinib is 
an oral tyrosine kinase receptor inhibitor whose mechanism 
of action is not inhibition of angiogenesis – it acts mainly by 
inhibiting the activity of the fusion protein bcr-abl. GISTs 
exhibit KIT mutations in exons 9, 11 or 13 in 85% of tumors 
and 5% have mutations in PDGFRα.57,58 Unfortunately, 
20% of patients demonstrate primary resistance to imatinib 
and secondary resistance occurs in patients after a year of 
treatment, characterized by mutations in KIT and PDGFRα 
kinases.59 In these patients, there were no effective therapeu-
tic options until the use of sunitinib was investigated.60
A phase III trial enrolled 312 patients who were resistant 
or intolerant to imatinib and randomized them to receive 
either sunitinib or placebo. The PFS for patients treated with 
sunitinib was 24.1 weeks compared to 6.4 weeks for patients 
in the placebo group (HR 0.33, P  0.0001). At the time of 
the initial analysis, more than half of the patients were still 
alive. The estimated median overall survival was better in the 
sunitinib group (HR 0.49, 95% CI 0.29 to 0.83).60 Patients in 
the placebo group were allowed to crossover to sunitinib after 
the trial was unblinded. The median overall survival from 
an updated analysis presented at the ASCO 2008 meeting 
did not show a clear survival benefit (HR 0.82, 95% CI not 
stated, P = 0.128). A statistical analysis, which tries to take 
into account the effect of the crossover, suggests there would 
have been a survival benefit (HR 0.46, P  0.0001) if the 
crossover had not been permitted.61
Adverse effects
The main side effects of sunitinib in phase II studies were 
fatigue, hypertension, nausea, diarrhea and mucositis. Hypo-
thyroidism was also recorded.49,50
Grade 3 or 4 hypertension, diarrhea, hand-foot syn-
drome, nausea, vomiting, mucositis, and bleeding were more 
common with sunitinib than with IFN-α. The grade 3 or 4 
laboratory abnormalities that were common with sunitinib 
were neutropenia, thrombocytopenia, leucopenia, increased 
lipase, increased amylase, hyponatremia, hyperuricemia, and 
hyperbilirubinemia.52OncoTargets and Therapy 2010:3 76
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The adverse effects of the TKIs can be divided into 
“on-target” and “off-target”. The on-target adverse effects 
are those that would be expected from their mechanism of 
action and include hypertension, proteinuria and hemorrhage. 
The off-target adverse effects include fatigue, diarrhea and 
nausea. The off-target effects are postulated to be due to the 
effects of TKIs on other kinases, complications from the 
patient’s cancer and other illnesses.62
Thalidomide
Thalidomide was the most recent angiogenesis inhibitor to 
be approved by the FDA.
Thalidomide is a potent angiogenesis inhibitor. The 
use of this drug had been limited as it was withdrawn from 
the market due to teratogenicity but, in recent years, there 
has been a renewed interest in the use of thalidomide as an 
antitumor agent.
Thalidomide inhibits the activity of basic fibroblast 
growth factor-2 (bFGF). This peptide has an effect on endo-
thelial cells by interacting with heparan-sulfate proteoglycans 
and tyrosine kinase FGF receptors. Thalidomide thereby 
inhibits angiogenesis.63–65 Thalidomide may also have other 
antitumor properties such as inhibition of tumor necrosis 
  factor alpha and alteration of expression of endothelial 
  cellular adhesion molecules.66,67
There have been several studies testing the role of tha-
lidomide in solid tumors. These have all shown disappointing 
results. The reasons for this are unclear. The main indication 
for thalidomide therapy is in the treatment of patients with 
myeloma. In May 2006, the FDA approved its use with 
dexamethasone for the treatment of patients newly diagnosed 
with multiple myeloma.
Combination with dexamethasone
In patients with myeloma, trials have shown that chemo-
therapy followed by stem cell transplantation provides the 
best overall survival for suitable patients.68,69 Thalidomide 
with dexamethasone is now accepted as an effective induc-
tion therapy for newly diagnosed myeloma patients who are 
suitable for stem cell transplantation.
An ECOG phase III study compared thalidomide plus 
dexamethasone versus dexamethasone alone in 207 patients 
with newly diagnosed myeloma. The response rate with thalid-
omide and dexamethasone was 63% compared to 41% for the 
patients who received only dexamethasone (P = 0.0017).70
A further phase III study made the same comparison in 
470 newly diagnosed myeloma patients. The response rate 
with thalidomide and dexamethasone was 63% compared 
to 46% with dexamethasone alone. The median time to 
progression was significantly better in the group that received 
thalidomide (22.6 versus 6.5 months, P  0.001).71
A case-control study compared thalidomide and dexametha-
sone versus vincristine, doxorubicin and dexamethasone (VAD) 
as induction therapy prior to autologous peripheral blood stem 
cell transplantation. Thalidomide and dexamethasone produced 
a higher response rate than VAD (76% versus 52%, P  0.001). 
There was also a greater reduction in myeloma cell mass of 
immunoglobulin G (IgG) and immunoglobulin A (IgA) types 
with thalidomide and dexamethasone.72
Combination with cytotoxic 
chemotherapy
In elderly patients with myeloma who are unsuitable for a 
stem cell transplant, the standard of care for several decades 
has been oral melphalan and prednisone.73
There have been three published randomized, controlled 
phase III trials comparing melphalan and prednisone with or 
without thalidomide.
In a study by the Italian Multiple Myeloma Network, 
255 patients aged 60 to 85 were randomized to have mel-
phalan and prednisone with or without thalidomide. The 
combined complete or partial response rates for patients 
who received thalidomide was 76.0% compared to 47.6% for 
patients who received only melphalan and prednisone (abso-
lute difference 28.3%, 95% CI 16.5% to 39.1%). The data 
do not currently show a survival benefit. The 3-year survival 
rates were 80% for patients receiving thalidomide and 64% 
without thalidomide (HR 0.68, 95% CI 0.38 to 1.22).73
A trial by the Intergroupe Francophone du Myélome 
(IFM) randomized 321 patients aged 65 to 75 into three 
groups. There was a significantly better overall survival 
in the group with melphalan, prednisone and thalidomide. 
Their median overall survival was 51.6 months compared to 
33.2 months for melphalan and prednisone alone (HR 0.59, 
95% CI 0.46 to 0.81) and 38.3 months for patients who had 
a reduced-intensity autologous stem cell transplant (HR 0.69, 
95% CI 0.49 to 0.96).74
The subsequent IFM 01/01 trial randomized 232 patients 
over 75 years old with newly diagnosed myeloma to hav-
ing melphalan and prednisone with or without thalidomide. 
Median overall survival was significantly better in the 
group that received thalidomide (44.0 versus 29.1 months, 
P = 0.001).75
These trials have established the role for thalidomide with 
melphalan and prednisone as the standard of care for patients 
unsuitable for stem cell transplantation.OncoTargets and Therapy 2010:3 77
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Adverse effects
The risk of severe teratogenicity and intra-uterine death 
with thalidomide is relatively high.76 In the United States, 
thalidomide can only be dispensed as part of the System for 
Thalidomide Education and Prescribing Safety (STEPS) 
program.77
An increased risk of venous thromboembolism (VTE) has 
been observed. Interestingly, when used as a single agent, 
there is no increase in the risk of VTE with thalidomide.78 
When thalidomide is combined with dexamethasone, then 
the risk of VTE ranges from 12% to 26% compared to 3% 
with dexamethasone alone.70,78,79 The risk of VTE is also 
high when thalidomide is combined with chemotherapy. 
In a study by Zangari et al, 100 patients were divided into 
2 groups with comparable myeloma prognostic factors and 
VTE risk factors. They were randomized to receive different 
combinations of dexamethasone, vincristine, doxorubicin, 
cyclophosphamide, etoposide, and cisplatin with or without 
thalidomide. The patients who received thalidomide had a 
28% VTE rate compared to 4% in the group who did not 
take thalidomide.80
Even in patients who do not have myeloma, the risk 
of VTE is significantly raised. For example, in a study of 
47 prostate cancer patients receiving docetaxel chemotherapy 
with or without thalidomide, 9 out of 47 patients (19%) 
receiving thalidomide developed VTE whilst none of the 
23 patients who received docetaxel alone developed VTE.81
Thalidomide also commonly causes the following adverse 
affects in at least 10% of patients – neutropenia, leucopenia, 
lymphopenia, anemia, thrombocytopenia, peripheral neurop-
athy, tremor, dizziness, paresthesia, dysesthesia, somnolence, 
constipation and peripheral edema.76
Thalidomide was the most recent angiogenesis inhibitor to 
be approved by the FDA but there are other drugs which are 
being developed for cancer patients. Following the develop-
ment of the first angiogenesis inhibitor, bevacizumab, other 
drugs have been designed in the laboratory to inhibit VEGF.
Aflibercept
Soluble VEGF receptors are a relatively new group of 
drugs. These drugs use decoy soluble receptors to bind 
VEGF and thereby prevent VEGF binding to its receptors. 
Aflibercept (AVE0005, VEGF-trap) is the most promising 
member of this group. It has the highest affinity for VEGF 
of any of the soluble VEGF receptors and aflibercept-
mediated blockade may be superior to that seen with the 
monoclonal antibody bevacizumab.82 It is a fully human-
ized, recombinant fusion protein. Aflibercept contains 
immunoglobulin (Ig) domains from VEGFR1 and 
VEGFR2 fused to the Fc segment of IgG1. Aflibercept 
has a high affinity for VEGF-A, VEGF-B and placental 
growth factor. Binding of these molecules to aflibercept 
prevents them binding to their normal target receptors and 
thereby suppresses angiogenesis. Aflibercept is currently 
being tested in phase III trials.
Combination with cytotoxic 
chemotherapy
The majority of trials with aflibercept consist of single 
agent phase I and II studies and most of the phase II studies 
are still in progress. There are, however, some randomized, 
controlled phase II and III trials evaluating aflibercept with 
chemotherapy.
The following trials are all currently recruiting patients.
The Southwest Oncology Group (SWOG) S0802 study is 
a phase II study comparing aflibercept with placebo combined 
with topotecan in patients with extensive stage small cell lung 
cancer who have previously been treated with platinum-based 
chemotherapy.83
VELOUR is a phase III study comparing aflibercept 
with placebo in combination with irinotecan and 5-FU in 
metastatic colorectal cancer patients having second-line 
chemotherapy.84
VITAL is a phase III study evaluating docetaxel with 
aflibercept or placebo in patients as second-line treatment 
for patients with locally advanced or metastatic non-small 
cell lung cancer.85
VENICE is a phase III study comparing aflibercept with 
placebo in combination with docetaxel and prednisone in 
patients with metastatic androgen independent prostate 
cancer.86
Adverse effects
Aflibercept is generally well tolerated. Toxicities that occur 
in more than 10% of patients are hypertension, headache, 
proteinuria, fatigue, dysphonia, bleeding (epistaxis and 
hemoptysis), anorexia, abdominal pain, nausea, diarrhea, 
constipation and arthralgia. Grade 3 to 4 hypertension 
occurs in more than 10% of patients; the remaining grade 3 
to 4 toxicities occur in less than 10% of patients and include 
headache, asthenia, anorexia and arthralgia. Venous throm-
boembolism, bleeding and perforation occur in less than 
1% of patients.87
The drugs discussed so far have all focused on inhibiting 
the growth of new blood vessels. The vascular disrupting 
agents act in a completely different manner and this final OncoTargets and Therapy 2010:3 78
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category of angiogenesis inhibitors may be one of the most 
promising groups of drugs under development.
Vascular disrupting agents
The vascular disrupting agents (VDAs) can target established 
tumor blood vessels. They act by causing a change in shape of 
the endothelial cells in the tumor’s vasculature causing vessel 
leakiness, thrombus, and increased interstitial pressure. They 
can also cause physical blockage of the blood vessel due to a 
combination of rouleaux formation and slowing of blood flow 
leading to increased viscosity.88 This leads to ischemia and 
necrosis of most of the tumor but a peripheral rim of viable 
cells usually remains. This class of drugs should work best 
when combined with other anti-tumor treatments in order to 
eliminate the rim of viable tumor cells.
There are two main classes of VDAs.
The biological (ligand-directed) VDAs combine an 
endothelium-targeting molecule with a toxin or pro-coagulant 
(Table 3).
The small molecule VDAs comprise the flavonoids and 
the tubulin-binding agents. The flavonoids act in a number 
of ways including cytokine induction and induction of apop-
tosis in endothelial cells. The tubulin-binding agents cause 
depolymerization of microtubules and disorganization of 
actin and tubulin.
These agents are currently under development. The agent 
that is in the most advanced stages of clinical evaluation is 
combretastatin. This drug is discussed below. For further 
information on all the other VDAs, the reader is directed to 
reviews by Gaya and Rustin90 and Lippert.91
Combretastatin
Combretastatin A4 was originally isolated from the bark 
of the African willow tree Combretum caffrum. Combre-
tastatin A4 phosphate is a water-soluble prodrug that is 
converted by endogenous phosphatases to the active drug. 
  Combretastatin is a tubulin-binding agent. Animal studies 
show that tumor blood flow can drop by more than 95%, one 
hour after administration.88 There is extensive necrosis and 
this effect is relatively selective for tumors.92
Phase I studies showed encouraging response rates in a 
variety of tumor types and one patient with anaplastic thyroid 
cancer experienced a complete response and has remained 
disease-free for 5 years.93
Combination with cytotoxic 
chemotherapy
There are interim reports from 4 phase I/II trials examining 
combretastatin with chemotherapy. Three of these trials were 
with a mixture of patients with refractory solid tumors. In 
one study, 4 out of 16 patients (25%) had stable disease with 
carboplatin and combretastatin.94 In a study with 27 patients, 
4 (15%) achieved a partial response and 17 (63%) had stable 
disease when treated with combretastatin and either carbo-
platin, paclitaxel, or a combination of both.95 In a further 
study with 13 patients, 3 (23%) had a partial response and 
6 (46%) had stable disease with carboplatin, paclitaxel and 
combretastatin.96 The remaining study involved 23 patients 
with platinum-resistant ovarian cancer treated with carbo-
platin, paclitaxel and combretastatin. There were six patients 
(26%) with confirmed partial responses.97
Combination with bevacizumab
A study using a murine model of human clear cell renal carci-
noma showed a significantly enhanced antitumor effect when 
bevacizumab and combretastatin were combined.98 Results are 
awaited from a completed phase I study with this drug combi-
nation in patients with advanced solid tumors.99 A randomized 
phase II study is currently examining carboplatin, paclitaxel 
and bevacizumab with or without combretastatin in chemo-
therapy naïve patients with non-small cell lung cancer.100
Combination with radiation therapy
There are reports of combretastatin significantly enhancing 
the effects of radiation in animal tumor models.101–105 There is 
a study of eight patients with non-small cell lung cancer who 
were given combretastatin after the second of six fractions 
of palliative radiotherapy. There was a significant decrease 
in tumor blood flow and increase in vascular permeability at 
4 hours and 72 hours after combretastatin administration.106
Adverse effects
The dose-limiting toxicity is reversible ataxia. Other effects 
include vasovagal syncope, motor neuropathy and ischemia in 
Table 3 Examples of biological vascular disrupting agents89
Agent Mechanism of action
Anti-endoglin-ricin A Antibody bound to a toxin
Anti-TES-23-neocarzinostatin Antibody bound to a cytotoxic agent
Anti-VCAM-1-tissue factor Antibody bound to tissue factor 
(induces intravascular thrombosis)
L19 scFv-IL-12 Antibody bound to a cytokine
L19 scFv-TNFα Antibody bound to a cytokine
VEGF-gelonin Growth factor bound to a plant toxin
Abbreviations: IL, interleukin; TES, tissue endothelium specific; TNF, tumor necrosis 
factor; scFv, single chain variable fragment; VCAM, vascular cell adhesion molecule; 
VEGF, vascular endothelial growth factor.OncoTargets and Therapy 2010:3 79
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previously irradiated bowel, tumor pain, dyspnea and cardiac 
ischemia.107–109 Other drug-related toxicities are pain, lympho-
penia, fatigue, anemia, diarrhea, hypertension, hypotension, 
vomiting, visual disturbance, and dyspnea.109
Although the VDAs are at an earlier stage of development 
than the other drugs discussed, they are the most exciting 
class of drugs. Unlike the other drugs discussed, they can 
target established tumor vasculature which provides them 
with a unique and promising potential role in treating cancer. 
They need to be combined with other therapies as, on their 
own, they leave a peripheral rim of viable tumor cells.
Conclusions
Anti-angiogenesis drugs have already proven their value in 
the management of a number of different cancers. These 
drugs have non-overlapping toxicities with other therapies 
and a synergistic action.
Bevacizumab, sorafenib, and sunitinib have all proven 
their use in randomized phase III trials in several different 
solid tumor types. These drugs have a proven role in the 
metastatic setting but may not be as effective in the adjuvant 
setting. There is some evidence to suggest that their effects 
may be transient in this patient group but the results of further 
studies are awaited.
Thalidomide has established itself as the standard of care 
in the treatment of myeloma but has had disappointing results 
in solid tumors. The reasons for this are unclear.
Aflibercept is a promising agent which may be more 
active than bevacizumab due to its higher affinity for VEGF. 
This drug therefore has the potential to treat the same tumor 
types as bevacizumab but more effectively.
The vascular disrupting agents are less developed than 
the other drugs in this review however they are potentially 
the most exciting and promising group. They have varied 
mechanisms of action but they all act by disrupting exist-
ing tumor vasculature. The other drugs described in this 
review only have the ability to inhibit the growth of new 
vasculature.
The results of further studies currently in progress may 
lead to the increasing use of anti-angiogenesis therapies as 
part of multi-modality therapy with acceptable toxicity.
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